Latest News - Novartis

Tuesday, June 20, 2017 | Clinical Trials, AMD, Novartis

Novartis RTH258 (Brolucizumab) Demonstrates Robust Visual Gains in Wet AMD Patients with a Majority on a 12-week Injection Interval

Novartis reported that RTH258 (brolucizumab) 6 mg met the primary and key secondary endpoints in two phase 3 studies, HAWK and HARRIER. RTH258 3 mg, evaluated in HAWK, also met these endpoints. These …

Read the full story

Wednesday, April 12, 2017 | Partnerships, Novartis

Commentary: Novartis Finds Its Next Mass-Market Ophthalmology Drug Candidate at a Small Virtual Biotech With a Global View

Like me, you may never have heard about Lubris BioPharma before today. But Novartis has. And that is by far more important. Today the pharma giant reached out and exercised an option on a recombinant …

Read the full story

Wednesday, January 25, 2017 | Earnings & Financials, Alcon, Novartis

Novartis Considers Spinning Off Alcon Unit

Novartis said it is considering several options for its Alcon unit, including the possibility of separating from the eye care division. The announcement comes after Novartis reported that Alcon’…

Read the full story

Wednesday, January 18, 2017 | Health Care, Novartis

Novartis CEO: Trump Could Boost Economy but Obamacare Needs to be Replaced if Repealed

Donald Trump's policies could be good for the economy but Obamacare should be replaced if it's repealed, the CEO of drug giant Novartis told CNBC on Tuesday. Joseph Jimenez played down some of…

Read the full story

Tuesday, December 20, 2016 | Acquisitions/Mergers, Novartis

Novartis Bolsters Ophthalmology Pipeline Through Acquisition of Encore Vision

Novartis announced that it has entered into a definitive agreement to acquire Encore Vision, a company focused on the development of a novel treatment in presbyopia. Terms of the deal were not disc…

Read the full story

Monday, November 21, 2016 | Miscellaneous, Alcon, Novartis

Novartis Backs Off From 2016 Date for Testing Google Autofocus Lens

Novartis has abandoned a 2016 goal to start testing its autofocus contact lens on people, though it said the groundbreaking product it is making with internet giant Google is "progressing steadil…

Read the full story

Friday, October 14, 2016 | Retina, Novartis

Lucentis Recommended by CHMP for EU Approval in Sixth Indication for the Treatment of Visually Impaired Patients

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Lucentis (ranibizumab) to treat patients with visual impairment due to choroidal ne…

Read the full story

Thursday, September 01, 2016 | Miscellaneous, Novartis

Novartis Dissolves Its Cell Therapy Unit, Cutting 120 Positions

Novartis AG said it will fold its specialized cell and gene therapies unit into other parts of the company, leading to about 120 job cuts months before seeking approval for a new type of cancer treatm…

Read the full story

Friday, June 24, 2016 | Retina, Novartis

CHMP Positive Opinion for Once-Daily Nevanac 3mg/ml (Nepafenac) Eye Drops in Europe

On June 24, 2016, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of once-daily Nevanac 3mg/ml (nepafenac) eye drops, suspension in Europe for the reduction in risk …

Read the full story

Tuesday, April 26, 2016 | Earnings & Financials, Novartis

Novartis May Sell Its $14 Billion Stake in Roche to Fuel Acquisitions

It was built over a decade ago as a basis for a possible merger that never happened. Novartis is discussing options with banks for selling its near $14 billion stake in rival Roche, potentially provid…

Read the full story

Thursday, March 31, 2016 | Earnings & Financials, Novartis

Novartis Publishes Updated 2015 Segment Financials Reflecting New Division Structure

Novartis announced that it has published updated 2015 quarterly and full-year segment financials reflecting the new division structure, as announced in the January 27, 2016 earnings release, as if the…

Read the full story

Wednesday, March 30, 2016 | Acquisitions/Mergers, Novartis

Sun Pharma Enters Japanese Prescription Market

Sun Pharma announced the acquisition of 14 established prescription brands from Novartis AG and Novartis Pharma AG in Japan in a deal valued at $293 million. According to the agreements ente…

Read the full story

Wednesday, January 27, 2016 | Earnings & Financials, Alcon, Novartis

Novartis Announces Major Restructure and Leadership Change to its Alcon Division

Novartis outlined a wide-reaching restructuring plan in an attempt to revive its struggling Alcon unit with the goal of returning its eye care business to growth by the end of the year. As part of …

Read the full story

Thursday, October 29, 2015 | Earnings & Financials, Novartis

Novartis Shells Out $390M to Settle Specialty Pharmacy Kickback Claims

Novartis agreed to pay about $390 million to wrap up federal kickback claims before the $3.3 billion case went to trial. The Justice Department and a number of U.S. states had sought up to $3.4 billio…

Read the full story

Friday, September 11, 2015 | Miscellaneous, Novartis

Novartis to Start Human Tests With Google Lens in 2016

Novartis plans the first human tests next year of a "smart" contact lens it is developing with Google designed to help restore the eye's natural autofocus. "This project is progress…

Read the full story
Load More